Virtue Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Virtue Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-501	Closed	-$282K	–	341
2025 Q3	$282K	Hold	501	–	–	0.04%	249
2025 Q2	$263K	Buy	+501	New	+$280K	0.05%	218
2021 Q4	–	Sell	-360	Closed	-$218K	–	433
2021 Q3	$218K	Sell	360 -65	-15%	-$40.4K	0.04%	355
2021 Q2	$237K	Hold	425	–	–	0.05%	288
2021 Q1	$201K	Buy	+425	New	+$207K	0.05%	272
2020 Q4	–	Sell	-2,597	Closed	-$1.45M	–	269
2020 Q3	$1.45M	Sell	2,597 -761	-23%	-$461K	0.36%	79
2020 Q2	$2.09M	Buy	+3,358	New	+$1.91M	0.48%	61

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Virtue Capital Management's REGN Position: Q4 2025 in Review

Virtue Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 501 shares — an estimated $282K sold.

Virtue Capital Management first reported a position in REGN in Q2 2020 and held it in 7 quarters. The position peaked at $2.09M in Q2 2020. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Virtue Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Virtue Capital Management sold 501 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $282K.
Virtue Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Virtue Capital Management's Regeneron Pharmaceuticals position peaked at $2.09M in Q2 2020.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Virtue Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.